AtomVie Global Radiopharma, a Hamilton, Ontario-based radiopharmaceutical contract development and manufacturing (CDMO), has opened a new $160 million manufacturing facility designed to support production from early development through commercialization.

The 72,300-square-foot facility provides low- to high-throughput production and increases AtomVie’s manufacturing capacity by more than tenfold, according to the company. The site includes space that can be configured for customers as their manufacturing requirements grow.

The facility represents a significant expansion of AtomVie’s ability to support radiopharmaceutical programs through development, clinical manufacturing, and commercial production. The company says the site is the largest single-site CDMO facility in North America dedicated to radiopharma development and manufacturing.

AtomVie is a spinout of the Centre for Probe Development and Commercialization, a McMaster University-based organization focused on radiopharmaceutical development and manufacturing. The company has supported more than 70 clinical development and technology transfer programs and manufactured more than 1,000 cGMP batches, according to the announcement.

The company said it has delivered more than 4,400 cGMP doses to patients in 28 countries across six continents. AtomVie plans to grow its workforce to more than 200 employees by the end of 2026, as the new facility scales toward full operations.

The Hamilton facility is intended to allow customers to transition radiopharmaceutical programs from early development into commercial manufacturing without moving production to another site. AtomVie’s existing capabilities include process and analytical method development, cGMP manufacturing, and global distribution.

The expansion comes as radiopharmaceutical developers, isotope producers, and CDMOs increase manufacturing capacity to support a growing pipeline of clinical and commercial therapies.

In May, Pharma Manufacturing reported that specialized manufacturers were scaling facilities to address expected demand and the challenges of handling short-lived radioactive products. RayzeBio, a Bristol Myers Squibb company, recently announced plans to invest more than $173 million in a new 225,000-square-foot radiopharma manufacturing facility in Whitestown, Indiana, complementing its existing Indianapolis operation.